AstraZeneca CEO Pascal Soriot Buys 60,000 Shares for £7.26M

A seven-figure open-market purchase by a sitting CEO is the kind of signal insiders rarely send by accident, and the four-day gap between the trade and its disclosure is the detail worth noting. It says nothing about the drug pipeline or the share price, but it does put Soriot's own capital alongside shareholders' at a moment when executive pay and alignment are under scrutiny. Whether other senior figures follow with their own purchases is the open question.